Abstract:Purpose: Mesangial cells-mediated glomerulonephritis refers to a category of immunologically mediated glomerular injuries characterized by infiltration of circulating inflammatory cells, proliferation of mesangial cells, and the common pathological manifestation to the later stage is renal fibrosis, accompanied by excessive accumulation of extracellular matrix (ECM). Treatment regimens include glucocorticoids and immunosuppressive agents, but their off-target distribution causes severe systemic toxicity. Hence, specific co-delivery of "anti-inflammatory/anti-fibrosis" drugs to the glomerular mesangial cell (MC) region is expected to produce better therapeutic effects. Methods: A novel kidney-targeted nanocarrier drug delivery system targeting MCs was constructed using passive targeting resulting from the difference in pore size between the glomerular endothelial layer and the basement membrane, and active targeting based on the specific binding of antibodies and antigens. Specifically, a liposome-nanoparticle hybrid (PLGA-LNHy) was formed by coating the surface of PLGA nanoparticles (NPs) with a phospholipid bilayer, and then PLGA-LNHy was co-modified with PEG and α8 integrin antibodies to obtain PLGA immunoliposomes (PLGA-ILs). Results: The results showed that the obtained NPs had a core-shell structure, uniform and suitable particle size (119.1 ± 2.31 nm), low cytotoxicity, and good mesangial cell-entry ability, which can successfully accumulate in the glomerular MC region. Both dexamethasone (DXMS) and captopril (CAP) were loaded onto PLGA-ILs with a drug loading of 10.22 ± 1.00% for DXMS and 6.37 ± 0.25% for CAP (DXMS/CAP@PLGA-ILs). In vivo pharmacodynamics showed that DXMS/CAP@PLGA-ILs can effectively improve the pathological changes in the mesangial area and positive expression of proliferating cell nuclear antigen (PCNA) in glomeruli as well as reduce the expression of inflammatory factors, fibrotic factors and reactive oxygen species (ROS). Thus, renal inflammation and fibrosis were relieved. Conclusion: We have provided a strategy to increase nanoparticle accumulation in MCs with the potential to implement regulatory effects of anti-inflammatory and anti-fibrosis in glomerulonephritis (GN).

Targeted drug delivery to renal proximal tubule epithelial cells mediated by 2-glucosamine

Prednisolone Succinate-Glucosamine Conjugate: Synthesis, Characterization and in Vitro Cellular Uptake by Kidney Cell Lines

Prednisolone-Glucose Derivative Conjugate: Synthesis, Biodistribution and Pharmacodynamics Evaluation

Synthesis and in Vivo Distribution of 2-Deoxy-2-aminodiglucose-prednisolone Conjugate（dpc）

Codelivery of Emodin and Diammonium Glycyrrhizinate by Anti-alpha8 Integrin-Conjugated Immunoliposomes for the Treatment of Renal Fibrosis

[Kidney-Targeting Characteristics of N-acetyl-L-glutamic Prednisolone Prodrug].

Randomly 50%N-Acetylated Low Molecular Weight Chitosan As a Novel Renal Targeting Carrier

Red blood cell membrane-camouflaged prednisolone acetate-loaded PLGA nanoparticles for kidney-targeted drug delivery

Effects of mycophenolic acid-glucosamine conjugates on the base of kidney targeted drug delivery.

Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect

Design and Evaluation of Glomerulus Mesangium-Targeted PEG-PLGA Nanoparticles Loaded with Dexamethasone Acetate

L-Carnitine ester of prednisolone: pharmacokinetic and pharmacodynamic evaluation of a type I prodrug.

Synthesis of an Enzyme—dependent Prodrug and Evaluation of Its Potential for Colon Targeting

Conjugating Glucosamine to Triptolide to Enhance Its Protective Effect Against Renal Ischemia-Reperfusion Injury and Reduce Its Toxicity

Glucocorticoids-based Prodrug Design: Current Strategies and Research Progress

Construction and Evaluation of Novel Αvβ3 Integrin Ligand-Conjugated Ultrasmall Star Polymer Micelles Targeted Glomerular Podocytes Through GFB Permeation

Synthesis and in vitro evaluation of kidney-targeted prodrug triptolide-glucosamine conjugate

Immuno-Nanoparticles Developed Using Dexamethasone and Captopril Co-Loaded PLGA Improve Glomerulonephritis Through Modulating Macrophage Polarization

Renal-specific Delivery of Prednisolone-Folate Conjugates for Renal Ischemia/reperfusion Injury

Co-Delivery of Dexamethasone and Captopril by α8 Integrin Antibodies Modified Liposome-PLGA Nanoparticle Hybrids for Targeted Anti-Inflammatory/Anti-Fibrosis Therapy of Glomerulonephritis

Inflammation-targeted Sialic Acid-Dexamethasone Conjugates for Reducing the Side Effects of Glucocorticoids